Breaking News

DSM, Crucell License PER.C6 To Masterclone

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM and Crucell entered a non-exclusive PER.C6 research licensing agreement with Russia-based Masterclone. Masterclone will use Crucell’s technology to develop an undisclosed antibody. Financial details were not disclosed. The PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as vaccines and proteins....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters